Clinical observation on nimotuzumab combined with radiochemotherapy in locoregionally advanced nasopharyngeal carcinoma
10.3760/cma.j.issn.1006-9801.2013.10.013
- VernacularTitle:尼妥珠单抗联合放化疗治疗局部晚期鼻咽癌的临床观察
- Author:
Juying LIU
;
Wei CHEN
;
Jing WEN
;
Yesong GUO
;
Xuesong JIANG
;
Xiuhua BIAN
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms;
Nimotuzumab;
Radiotherapy;
Chemotherapy
- From:
Cancer Research and Clinic
2013;25(10):696-699
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of nimotuzumab in combination with radiochemotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC).Methods 42 patients with locoregionally advanced NPC were retrospectively analyzed.They all received the treatment of nimotuzumab in combination with radiochemotherapy.Intensity modulated radiationtherapy (IMRT) was applied and the prescribed radiation dose administered to the primary tumor was between 70 to 79.2 Gy in 32-37 fractions and 41-49 days.The dose administered to lymph nodes was between 65 to 76 Gy in 32-37 fractions and 41-49 days.Nimotuzumab was given weekly during irradiation.All patients received chemotherapy.Results The main adverse events were mucositis,bone marrow suppression,dermatitis and xerostomia.Grade 1 or 2 oropharyngeal mucositis occurred in 29 (69.0 ％) patients,and grade 3 in 2 (4.8 ％).Grade 1 or 2,3 or 4 leucopemia occurred in 25 cases (59.5 ％),16 cases (38.1％),respectively,without occurrence of febrile neutropenia.There was no treatment related death.Complete response (CR) rate was 90.5 ％ (38/42),partial response (PR) rate was 9.5 ％ (4/42) and the total efficiency was 100 ％.After a median follow-up of 22.5 months,the 1-year local control rate was 100 ％.1-year distant metastasis-free survival rate was 92.7 ％.1-year overall survival rate was 95.2 ％.Conclusion Nimotuzumab combined with radiochemotherapy was efficient and safe for locoregionally advanced NPC.
